Clinical trial
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With…
NCT04149574 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT04149574 |
|---|---|
| Title | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) |
| Official title | A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG |
| Acronym | CheckMate 7G8 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urinary Bladder Neoplasms |
| Intervention type | Biological, Drug, Other |
| Interventions | nivolumab, Placebo, Bacillus Calmette-Guérin (BCG) |
| Enrollment | 13 |
| Start date | Jan 15, 2020 |
| Primary completion | Oct 31, 2023 |
| Completion | Oct 31, 2023 |
| First posted | Nov 4, 2019 |
| Last update posted | Sep 16, 2025 |
| Countries | Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Italy, Netherlands and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: